Compare Okta, Inc. (OKTA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Sanofi SA — how do they compare? Okta, Inc. trades at $136.38 (market cap $24.63B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 4.3× Okta, Inc.'s market cap, and Sanofi SA pays a 5.53% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| OKTA | SNY | |
|---|---|---|
Market Cap | $24.63B | $104.85B |
Sector | Technology | Health |
52-Week High | $154.62 | $52.34 |
52-Week Low | $62.93 | $41.33 |
Enterprise Value | $22.45B | $121.38B |
Dividend Yield | — | 5.53% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
